Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection

Annals of Pharmacotherapy

Volumn 34, Issue 4, 2000, Pages 487-494

  Battaglia, Andrea M ^a,b   Hagmeyer, Kathleen O ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b Henry Ford Health Systems   (United States)

Author keywords

Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0034039676     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19183     Document Type: Review

References (51)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
2. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(suppl 1):15S-20S.
3. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morbid Mortal Wkly Rep 1998;47:1-39.
4. Tillman HL, Manns MP. Hepatitis C virus infection: diagnosis, natural course, and therapy. Kidney Blood Press Res 1996;19:215-9.
5. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(suppl 1): 62S-5S.
6. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125:658-68.
7. Colquhoun SD. Hepatitis C: a clinical update. Arch Surg 1996;131:18-23.
8. Purcell R. The hepatitis C virus: overview. Hepatology 1997;26(suppl 1):11S-4S.
9. National Institutes of Health Development Consensus Development Panel: management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
10. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future applications. Mayo Clin Proc 1996;71:458-62.
11. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the ND-5 region. J Gen Virol 1993;74:2391-9.
12. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, et al. Hepatitis C virus type lb (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
13. Pozzato G, Moretti M, Franzin F, Croce LS, Tiribelli C, Masayu T, et al. Severity of liver disease with different hepatitis C viral clones (letter). Lancet 1991;338:509.
14. Zein NN, Rokela J, Krawitt EL, Reddy R, Tominaga T, Persing DH, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125:634-9.
15. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-95.
16. Kanazawa Y, Hayash N, Mita E, Tiancheng L, Hagiwara H, Akinori K, et al. Influence of quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
17. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994;39:241-75.
18. Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995;2:121-32.
19. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26(suppl 1):71S-7S.
20. Van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-9.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994;19:1513-20.
22. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
23. Fattovich G, Ciustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112: 463-72.
24. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
25. Schiff ER. Hepatitis C and alcohol. Hepatology 1997;26(suppl 1):39S-42S.
26. Rothstein KD, Munoz SJ. Interferon and other therapies for hepatitis B and hepatitis C infections. Clin Lab Med 1996;16:465-91.
27. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S-7S.
28. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouser JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-6.
29. Matinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Ploiquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
30. Package insert. Intron-A (interferon alfa-2b, recombinant). Kenilworth, NJ: Schering, 1998.
31. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986;30:201-5.
32. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-46.
33. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepalology 1997;26(suppl 1):108S-11S.
34. Package insert. Rebetron (ribavirin capsules and interferon alfa-2b injection). Kenilworth, NJ: Schering-Plough, May 1998.
35. Camps J, Garcia N, Reizu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-12.
36. Dusheiko G, Main J, Thomas H, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
37. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C: a randomized double blind placebo-controlled trial. Ann Intern Med 1995;123: 897-903.
38. Branconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995;27:325-9.
39. Brillanti S, Garson J, Foli M, Whitby K, Deaville CM, Miglioli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 10:812-7.
40. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995;23(suppl 2): 13-6.
41. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23(suppl 2): 17-21.
42. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-7.
43. Chemello L, Cavalletta L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995;23(suppl 2):8-12.
44. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Longterm efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
45. Reichard O, Norkrans G, Fryden A, Branconier JH, Anders S, Weiland O, et al. Randomised double blind placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-7.
46. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
47. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
48. Davis GL, Esteban-Mur R, Vinod R, Hoef J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
49. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-65.
50. Kim WR, Poterucha JJ, Hermans JE, Themeau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
51. Kim WR, Poterucha JJ, Dickson ER, Gross JB. Economics analysis of interferon/ribavirin treatment in patients with chronic hepatitis C who relapse following initial interferon therapy (abstract). Gastroenterology 1998;114:1274A.